ReleaseWire Connect

“Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth”. The report focuses on the current scenario of orally administered drugs. Key segment of orally administered drugs which are covered in the report include small molecules, proteins, peptides and vaccines. The oral drug delivery market is forecast to show increase in the forecast period (2010-2017) due to increase in demand for innovative oral drugs. The report analyses marketed oral drugs based on molecule type and indication. Pipeline drugs by molecule type are discussed in detail. The report analyses different types of nano-technology which will decide the future of orally administered drugs. Key drug delivery companies are profiled with their proprietary technologies, pipeline molecules and deals. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

“Iron Ore Mining Market in Asia-Pacific to 2020 - Interplay Between Regional Demand for Steel and Iron Production Shapes the Competitive Landscape” provides key information and analysis of the Asia-Pacific iron ore mining industry that comprises China, Australia, India and Kazakhstan. The report covers the industry’s drivers and restraints, production, reserves, consumption and details of country’s trade (imports and exports. This report is based on data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

This first edition of The Douglas-Westwood World Subsea Vessel Operations Market 2011-2015 forecasts strong recovery in vessel demand. Expenditure is set to grow 52%, totaling $72bn between 2011 and 2015.

“Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation”, which provides insights into the orphan disease therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of Fabry, Pompe, Mucopolysaccharidosis VI, Idiopathic Thrombocytopenic Purpura, Huntington’s Disease and Ovarian cancer. The report examines the global orphan diseases therapeutics treatment usage patterns. It includes the geographical distribution of Fabry, Pompe, Mucopolysaccharidosis VI, Idiopathic Thrombocytopenic Purpura, Huntington’s Disease and Ovarian cancer markets across the US, the top five countries of Europe and in Japan. The report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

A bright future is forecast for the LNG industry, as growing long-term gas demand drives major investment in global LNG facilities. The World LNG Market Report 2011-2015, from award-winning energy business advisors Douglas-Westwood (DW), predicts the Pacific basin will be the main contributor to a ten-year global investment high of $26 billion per annum by 2015. World spend is forecast to recover momentum and Capex on LNG facilities for the 2011-2015 period is expected to total over $93 billion.

The new edition of Douglas-Westwood’s World Floating Production Report forecasts capital expenditure over the next five years will total $68 billion.

Smart Cities Market (2011 - 2016) - Projects, Advanced Technologies, Adoptions and Transformations - Worldwide Market Report

“Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules”, which provides insights into the Oncology orphan disease therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of pancreatic cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia as well as Hodgkin lymphoma in the last seven years as well as throughout the forecast period until 2018. The report examines the global orphan diseases therapeutics in Oncology usage patterns. It includes the geographical distribution of pancreatic cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia and Hodgkin lymphoma markets across the US, the top five European countries and in Japan. The report also includes insights into the orphan diseases therapeutics in Oncology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the Oncology orphan disease therapeutics market. Finally, the report includes an analysis of Mergers and Acquisitions (M&A) as well as co-development and licensing deals that took place in the orphan diseases therapeutics in Oncology market in the last seven years.

“Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments”, which provides insights into autoimmune disease therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides in-depth analysis of the main autoimmune diseases, which are Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Psoriasis, Inflammatory Bowel Disease (IBD) including Crohn’s Disease (CD) and Ulcerative Colitis (UC), and Systemic Lupus Erythematosus (SLE). The report also gives the share of generic drugs in global autoimmune diseases, as well as in each indication’s market. It examines global autoimmune diseases treatment usage patterns and the geographical distribution of autoimmune diseases and the markets in the US, the top five countries of Europe, and Japan. The report also includes insights into the R&D product pipeline and explores the competitive landscape with profiles of major players. Finally, it includes analysis of Mergers and Acquisitions (M&A) and licensing agreements that have taken place in autoimmune diseases therapeutics market from 2009 to 2011.

Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall”, provides an in-depth analysis on medical device recalls in the US. The report analyzes the number of medical device recalls in the US by year, recall class, therapeutic area and root cause from 2005–2010. The report includes an in-depth analysis on medical device recalls by the top 10 recall firms, with the number of device recalls by year and by recall class. The report presents information on medical device regulatory systems, with emphasis on regulatory intelligence in the following seven countries: the US, the UK, Germany, France, Spain, Italy and Japan. The medical equipment approval process, device classification, conformity assessment process and post-market surveillance are explained in the report.